These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21441783)

  • 1. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
    Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
    Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.
    Iwata S; Nakata S; Ukae S; Koizumi Y; Morita Y; Kuroki H; Tanaka Y; Shizuya T; Schödel F; Brown ML; Lawrence J
    Hum Vaccin Immunother; 2013 Aug; 9(8):1626-33. PubMed ID: 23732903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).
    Itzler R; Koch G; Matson DO; Gothefors L; Van Damme P; Dinubile MJ; Heaton PM
    BMC Pediatr; 2010 Jun; 10():42. PubMed ID: 20540778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.
    Mo Z; Mo Y; Li M; Tao J; Yang X; Kong J; Wei D; Fu B; Liao X; Chu J; Qiu Y; Hille DA; Nelson M; Kaplan SS
    Vaccine; 2017 Oct; 35(43):5897-5904. PubMed ID: 28935470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
    Sow SO; Tapia M; Haidara FC; Ciarlet M; Diallo F; Kodio M; Doumbia M; Dembélé RD; Traoré O; Onwuchekwa UU; Lewis KD; Victor JC; Steele AD; Neuzil KM; Kotloff KL; Levine MM
    Vaccine; 2012 Apr; 30 Suppl 1():A71-8. PubMed ID: 22520140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
    Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
    Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
    Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
    Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
    Feikin DR; Laserson KF; Ojwando J; Nyambane G; Ssempijja V; Audi A; Nyakundi D; Oyieko J; Dallas MJ; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A52-60. PubMed ID: 22520137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.
    Vesikari T; Karvonen A; Ferrante SA; Ciarlet M
    Eur J Pediatr; 2010 Nov; 169(11):1379-86. PubMed ID: 20559656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
    Leshem E; Givon-Lavi N; Tate JE; Greenberg D; Parashar UD; Dagan R
    Clin Infect Dis; 2016 May; 62 Suppl 2():S155-60. PubMed ID: 27059350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
    Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.
    Vesikari T; Karvonen A; Ferrante SA; Kuter BJ; Ciarlet M
    Pediatr Infect Dis J; 2010 Oct; 29(10):957-63. PubMed ID: 20442684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States.
    Weycker D; Atwood MA; Standaert B; Krishnarajah G
    Hum Vaccin Immunother; 2014; 10(7):2032-8. PubMed ID: 25424813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013.
    Payne DC; Selvarangan R; Azimi PH; Boom JA; Englund JA; Staat MA; Halasa NB; Weinberg GA; Szilagyi PG; Chappell J; McNeal M; Klein EJ; Sahni LC; Johnston SH; Harrison CJ; Baker CJ; Bernstein DI; Moffatt ME; Tate JE; Mijatovic-Rustempasic S; Esona MD; Wikswo ME; Curns AT; Sulemana I; Bowen MD; Gentsch JR; Parashar UD
    Clin Infect Dis; 2015 Dec; 61(12):1792-9. PubMed ID: 26449565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011.
    Payne DC; Boom JA; Staat MA; Edwards KM; Szilagyi PG; Klein EJ; Selvarangan R; Azimi PH; Harrison C; Moffatt M; Johnston SH; Sahni LC; Baker CJ; Rench MA; Donauer S; McNeal M; Chappell J; Weinberg GA; Tasslimi A; Tate JE; Wikswo M; Curns AT; Sulemana I; Mijatovic-Rustempasic S; Esona MD; Bowen MD; Gentsch JR; Parashar UD
    Clin Infect Dis; 2013 Jul; 57(1):13-20. PubMed ID: 23487388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the effectiveness of the pentavalent rotavirus vaccine against rotavirus hospitalizations and emergency department visits using two study designs.
    Donauer S; Payne DC; Edwards KM; Szilagyi PG; Hornung RW; Weinberg GA; Chappell J; Hall CB; Parashar UD; Staat MA
    Vaccine; 2013 May; 31(24):2692-7. PubMed ID: 23583814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.